Atrium Therapeutics, Inc.
SEC CIK 2093101 · RNA · last insider filing 2026-04-22
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Gallagher Kathleen P. | Director · See Remarks | filed 2026 - 2026 |
| Boess Carsten | Director | filed 2026 - 2026 |
| Wilson Troy Edward | Director | filed 2026 - 2026 |
| Boyce Sarah | Director | filed 2026 - 2026 |
| Flanagan W. Michael | Director | filed 2026 - 2026 |
| Skerjanec Simona | Director | filed 2026 - 2026 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Hughes Steven George | Chief Medical Officer | filed 2026 - 2026 |
| Kenney Stephanie | See Remarks | filed 2026 - 2026 |
| Winslow Brendan R. | Chief Financial Officer | filed 2026 - 2026 |
| Hoyos Rocio Martin | Chief Strategy Officer | filed 2026 - 2026 |
| Younis Husam | Chief Scientific Officer | filed 2026 - 2026 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.